Posts

The Global Imperative: Building Cognitive Resilience as Economic Infrastructure

The Global Imperative Building Cognitive Resilience as Economic Infrastructure AUTHOR: KJ Lavan   The global economy is entering a period of structural transformation unlike any in modern history.  Population aging, demographic transition, artificial intelligence, climate-related disruption, geopolitical uncertainty, and rapid technological change are redefining the foundations of economic growth and national competitiveness.  Together, these forces are reshaping how societies create value, sustain productivity, and build long-term resilience. At the center of this transformation lies an increasingly strategic asset: human cognitive capacity. Historically, investments in infrastructure have focused on transportation, energy, communications, water systems, and digital connectivity because they enable economic participation and productivity. Human cognition—the capacity to learn, reason, innovate, adapt, and make complex decisions—has generally been viewed through the narro...
Post a Comment
Read more

Series 7: The Last Mile of Brain Science

SERIES 7: THE LAST MILE OF BRAIN SCIENCE AUTHOR: KJ Lavan We Are Democratizing Detection Before Democratizing Care The next crisis in #Alzheimer’s disease may not be a shortage of scientific breakthroughs. It may be a shortage of systems capable of using them. The science is advancing rapidly. Lecanemab and donanemab can slow progression in appropriately selected people with early Alzheimer’s disease. But these therapies require confirmation of amyloid pathology, specialist evaluation, infusions, MRI monitoring and management of amyloid-related imaging abnormalities. ( U.S. Food and Drug Administration ⁠) In July 2026, the FDA approved an at-home starting dose of lecanemab—another step toward making treatment more accessible.  Yet, moving administration closer to the home does not eliminate the need for diagnosis, patient selection, safety surveillance and coordinated clinical oversight. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheim...
Post a Comment
Read more